Screener
Cogent Biosciences, Inc. COGT Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Cogent Biosciences, Inc.’s reported figures.
Based on the most recent quarter.
The source filing: Cogent Biosciences, Inc.’s 10-Q, filed May 5, 2026. Open the filing →
- Filed
- May 5, 2026, 8:21 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-205170
FAQ
- What is Cogent Biosciences, Inc.'s debt-to-equity?
- Cogent Biosciences, Inc. (COGT) reported debt-to-equity of 0× in Q1 2026.
- How has Cogent Biosciences, Inc.'s debt-to-equity changed year-over-year?
- Cogent Biosciences, Inc.'s debt-to-equity decreased by 67.3% year-over-year, from 0.1× to 0×.
- What is the long-term trend for Cogent Biosciences, Inc.'s debt-to-equity?
- Over 5 years (2020 to 2025), Cogent Biosciences, Inc.'s debt-to-equity has grown at a 2.4% compound annual growth rate (CAGR), from 0× to 0×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Cogent Biosciences, Inc.'s debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude